Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation

By  

Molecular and Clinical Oncology, Vol. 3, Iss. 2, 2015-01 ,pp. : 329-333

Science Publishers

Access to resources Recommend Favorite

Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma

By Ekman Simon   Fröödin Jan-Erik   Harmenberg Johan   Bergman Antonina   Hedlund ÅÅsa   Dahg Pia   Alvfors Carina   Stååhl Birgitta   Bergströöm Stefan   Bergqvist Michael  

Acta Oncologica, Vol. 50, Iss. 3, 2011-04 ,pp. : 441-447

Informa Healthcare

Access to resources Recommend Favorite

Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment

By                

Oncology Letters, Vol. 3, Iss. 6, 2012-01 ,pp. : 1288-1292

Spandidos Publications

Access to resources Recommend Favorite

Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer

By Chu Huili   Zhong Chen   Xue Guoliang   Liang Xiuju   Wang Jun   Liu Yingxin   Zhao Shiwei   Zhou Qian   Bi Jingwang  

Oncology Reports, Vol. 30, Iss. 5, 2013-11 ,pp. : 2311-2315

Spandidos Publications

Access to resources Recommend Favorite

Icotinib combined with rapamycin in a renal transplant recipient with epidermal growth factor receptormutated nonsmall cell lung cancer: A case report

By        

Oncology Letters, Vol. 7, Iss. 1, 2014-01 ,pp. : 171-176

Spandidos Publications

Access to resources Recommend Favorite